← Human Trials & Peer-Reviewed Studies
Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients
Plain-language guide to PMID 9829494 (1998): placebo-controlled randomized controlled trial study of Endothelin-1 in 10 patients.
Key Facts
- PMID
- 9829494
- Journal
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Kang DH et al. (3 authors)
- DOI
- 10.1093/ndt/13.11.2877
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Endothelin-1.
The purpose of this study was to ascertain the potential role of ECE in the development of rHuEpo-induced hypertension.
Why It Was Studied
The pathogenesis of rHuEpo-induced hypertension in haemodialysis (HD) patients still remains uncertain.
Endothelin-1 (ET-1) is produced from proendothelin-1 (proET-1) by an endothelin-converting enzyme.
Who Took Part
The abstract describes 10 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
Different routes of administration (19 intravenous group, 10 subcutaneous group) were compared to a placebo-injected control group (10 HD patients).
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Because people in this Endothelin-1 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some patients received a placebo instead of Endothelin-1, giving a reference point.
What Was Measured
PubMed files the paper under topics including Blood Pressure, Endothelin-1, Endothelins, Erythropoietin, Protein Precursors, Recombinant Proteins and Renal Dialysis.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Endothelin-1 in 10 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1998 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.
More context: the Endothelin-1 compound page, all human trials.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.